logo
  

Yamada To Pay $2.5 Mln Fine For Price Fixing

Yamada Manufacturing Co. Ltd. has agreed to plead guilty and to pay a $2.5 million criminal fine for its role in a conspiracy to fix prices and rig bids for manual (non-electric or non-hydraulic-powered) steering columns installed in cars sold in the United States and elsewhere, the U.S. Department of Justice announced.

According to a one-count felony charge filed today in U.S. District Court of the Southern District of Ohio in Cincinnati, Yamada Manufacturing, based in Kiryu City, Gunma Prefecture, Japan, conspired to rig bids and fix prices of steering columns sold to certain subsidiaries of Honda Motor Co. Ltd. (HMC) in the United States and elsewhere. According to the charge, Yamada carried out the conspiracy from at least as early as the fall of 2007 and continuing until as late as September 2012. Yamada Manufacturing has agreed to cooperate in the department's ongoing investigation.

According to the charge, Yamada Manufacturing, and others participating in the scheme, conspired through a meeting and conversations in which they discussed and agreed upon bids and price quotations to be submitted to Honda. Based on those discussions, Yamada Manufacturing and its co-conspirators sold steering columns to Honda at collusive and non-competitive prices and employed measures to keep their conduct secret.

Including Yamada Manufacturing, 35 companies and 29 executives have pleaded guilty or agreed to plead guilty in the division's ongoing investigation into price fixing and bid rigging in the auto parts industry and have agreed to pay a total of more than $2.5 billion in criminal fines.

Yamada Manufacturing is charged with one count of price fixing and bid rigging in violation of the Sherman Act, which carries maximum penalties of a $100 million criminal fine for corporations. The maximum fine may be increased to twice the gain derived from the crime or twice the loss suffered by the victims of the crime, if either of those amounts is greater than the statutory maximum fine.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT